Cyber Insurance for Biotech: Research Data Worth More Than You

The Company Might Be Worth Nothing Without the Data Behind It

A biotech firm developing a novel therapy can spend years and hundreds of millions of dollars before generating a dollar of revenue, which means its entire value sits inside research data, clinical trial results, and intellectual property rather than in physical assets or existing sales. If that data is stolen or destroyed, the company's worth can evaporate even though nothing physical was ever touched. Cyber insurance for biotech firms has to be built around this reality, treating research data protection as the core of the risk rather than a secondary concern behind more familiar categories like business interruption.

Why can research data be worth more than the company holding it?

Because a pre-revenue biotech's entire value often lies in its intellectual property, stolen or compromised research can eliminate the company's core worth without a single physical asset changing hands.

Unlike a manufacturing company that retains factories, equipment, and existing revenue even after a bad cyber incident, a biotech firm whose primary asset is proprietary research data has comparatively little left if that data is stolen, corrupted, or exposed to a competitor. This concentration of value into intangible research is exactly why underwriters treat biotech submissions differently from most other industries when assessing what is actually at stake in a breach.

Who is actually targeting biotech research data?

Both state-sponsored actors and commercial competitors pose real threats, given the strategic national interest and direct commercial value tied to novel drug and therapy research.

Unlike opportunistic ransomware crews looking for a quick payout, some of the actors targeting biotech firms are patient, well-resourced, and specifically interested in the research itself rather than any ransom payment, which changes the threat model underwriters need to account for. This is part of why encryption and access control practices get scrutinized so closely, since the goal for many attackers targeting this sector is theft, not disruption.

How does this change how insurers value a potential loss?

Standard data breach valuation, built around cost per exposed personal record, does not translate well to a scenario where the actual loss is stolen intellectual property with no fixed per-unit cost.

Valuing a stolen dataset of years of proprietary research requires a fundamentally different approach than valuing a breach of customer records, since the loss is tied to competitive advantage, patent timing, and potential regulatory approval pathways rather than a straightforward per-record cost model. Underwriters increasingly rely on a Cyber Insurance Risk Assessment Tools style approach adapted specifically to weigh research sensitivity and access exposure.

Does clinical trial data add a separate layer of risk?

Yes, clinical trial data combines sensitive personal health information from trial participants with valuable research findings, layering privacy regulation risk on top of pure IP theft risk.

A breach touching clinical trial data can trigger both the regulatory and notification obligations typical of a healthcare data breach and the competitive damage typical of stolen research, meaning a single incident can generate two very different categories of financial and legal consequence at once. This overlap is closely related to the exposure covered in Cyber Insurance for Healthcare Providers: Risk Beyond HIPAA Fines, applied to the research side of the life sciences industry rather than direct patient care.

Risk Dimension	What's at Stake	Insurance Consideration
Proprietary research/IP	Core company value	Requires custom valuation, not per-record pricing
Clinical trial participant data	Personal health information	Privacy regulation and notification obligations
M&A due diligence exposure	Sensitive data shared in data rooms	Additional access points during deal activity
State-sponsored threat actors	Patient, well-resourced targeting	Different threat model than opportunistic crime

Can a cyber incident actually affect a biotech company's ability to raise money?

Yes, investors increasingly review cybersecurity posture as part of due diligence, and a past breach or weak security posture can materially affect valuation and deal terms during a funding round.

For a sector as dependent on successive funding rounds as biotech, a security incident is not just an operational problem, it can directly complicate the next round of capital a company needs to keep operating, which gives cyber risk management a strategic weight beyond typical loss prevention.

Does M&A activity introduce its own cyber exposure?

Yes, due diligence processes and data rooms used during acquisitions create additional points where sensitive research data can be intercepted or exposed.

Sharing detailed research findings with a potential acquirer's due diligence team, often through third-party data room platforms, introduces exposure that would not exist outside of an active deal process. Insurnest's AI M&A Cyber Due Diligence for Insurance reflects how much this specific moment in a biotech company's lifecycle has become its own recognized risk category.

Biotech firms carry a version of cyber risk that most industries simply do not face in the same way, where the data itself, not the systems around it, represents nearly the entire value of the business. Underwriting this sector well means treating research protection as the central question, not a checkbox alongside more conventional cyber concerns, and biotech firms that can show real rigor here tend to find underwriters far more willing to engage with what is otherwise a genuinely hard risk to price.

Sources

• Cybersecurity Framework, National Institute of Standards and Technology (NIST)
• Cross-Sector Cybersecurity Performance Goals, Cybersecurity and Infrastructure Security Agency